We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Plea comes as continent’s top vaccine production plant faces uncertain future due to collapse in demand
The president announced the move at a virtual summit hosted by the US, Belize, Germany, Indonesia and Senegal
New modelling underscores country’s vulnerability because of faltering vaccination drive
German biotech maintains guidance but prepares for fall in sales because of jab oversupply
Pyongyang claims to have avoided a big outbreak but experts warn its luck will eventually run out
US drugmaker says demand for ‘bivalent booster’ could lift jab sales in second half of 2022
Vulnerable people feel they are forgotten because of government’s ‘living with Covid’ strategy
The problems threaten plans to produce 60 per cent of all vaccines administered in Africa locally by 2040
Revenue rises 60% as Alexion acquisition and its rare diseases medicines boost drugmaker’s earnings
Two top-10 shareholders say distribution problems not supply is reason for slower vaccination rates in low-income countries
UK drugmaker points to ‘good momentum’ as sales rise by a third in ‘landmark year’
Almost 20mn Beijing residents will have to undergo 3 rounds of tests by Saturday
‘There has been a change in attitudes. There are a lot of initiatives that were not foreseen a couple of years ago’
Do not dismiss the possibility of another upturn in the coronavirus testing market
Swiss pharmaceuticals group expects revenue from coronavirus treatments will decline this year
Biden’s flagship scheme giving antiviral pills to at-risk patients has run into multiple problems
Moderna’s chief says there is ‘massive oversupply’
Beijing ought to swallow its pride and approve foreign mRNA vaccines
Global body fears that lack of clarity may mean poorer countries lack access to Paxlovid
Other diseases kill more than coronavirus in the global south
Early clinical findings show that two-in-one shot could be safe and effective
Shares slide as London-listed group announces ‘pause’ in vaccine manufacturing
Omicron outbreak in Shanghai has refocused attention on waning efficacy of homegrown jabs
Proxy advisers back shareholder resolutions as new shot shows promising results
University spinout is developing two vaccines to help prevent future pandemics
International Edition
